Completed PHASE4 INTERVENTIONAL 2-arm NCT03490513

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

Sponsor: Baylor College of Medicine

Conditions Hypogonadism, Hypogonadotropic Obesity

Interventions Placebo anastrozole (1 mg/day)

Updated 12 times since 2018 Last updated: Aug 4, 2025 Started: Apr 15, 2018 Primary completion: May 31, 2025 Completion: May 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hypogonadism, Hypogonadotropic and Obesity, this trial is completed. The trial is conducted by Baylor College of Medicine and has accumulated 12 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4

Status: Recruiting → Completed
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE4
Mar 2023 — Apr 2024 [monthly]

Recruiting PHASE4

▶ Show 7 earlier versions

Feb 2022 — Mar 2023 [monthly]

Recruiting PHASE4
Feb 2021 — Feb 2022 [monthly]

Recruiting PHASE4
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE4
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE4
Aug 2018 — Feb 2020 [monthly]

Recruiting PHASE4
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE4
May 2018 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States